A comparison of current neuroblastoma chemotherapeutics |
| |
Authors: | Castel Victoria Cañete Adela |
| |
Institution: | Pediatric Oncology Unit, Hospital Infantil Universitario La Fe, Avda Campanar 21, 46009 Valencia, Spain. castel_vic@gva.es |
| |
Abstract: | Neuroblastoma is the most common solid tumour in childhood. Modern management includes a biopsy to perform genetic studies. Based on clinical data and Myc-N amplification (MNA), patients are divided in three prognostic groups: the low-risk (Stage 1, 2, 4S without MNA) has an event-free survival (EFS) of > 90% with surgery alone; the intermediate-risk (Stage 3, > 1 year of age, without MNA and Stage 3 and 4 infants without MNA) has an EFS of approximately 80% with mild chemotherapy and surgery; the high-risk group includes Stage 4, > 1 year of age and any stage and age with MNA. These patients are treated with chemotherapy, surgery, megatherapy, irradiation and 13-cis-retinoic acid. With this complex therapy, a 5-year EFS of 30-50% can be obtained. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|